For destructive-resistant prostate cancer, docetaxel-based chemotherapy is currently the first-line treatment option, especially in the context of treatment modalities such as abiraterone, enzalutamide, and radium-133 that are still not fully available in China, difficult to obtain drugs, and high drug prices. Therefore, docetaxel is crucial for the treatment of such patients, and for some patients, it can even be compared to the last straw without exaggeration. After reviewing the literature and guidelines, a more uniform answer is that for hormone-sensitive prostate cancer with more metastases, especially visceral metastases, docetaxel chemotherapy is usually administered for at least 6 cycles; for destructive-resistant prostate cancer, docetaxel chemotherapy is usually used for at least 10 cycles. The reasons are as follows: 1. For hormone-sensitive metastatic prostate cancer, the majority of current clinical studies have used 6 cycles of docetaxel chemotherapy. Patients who use chemotherapy have a more significant benefit, and a 6-cycle treatment regimen is now written into the guidelines as an optional treatment option. In other tumors, chemotherapy as adjuvant therapy is also usually given in 4-6 cycles. 2. For desmoid-resistant prostate cancer, it has been shown that patients treated with 8 or more cycles of chemotherapy have significantly higher overall survival than those treated with less than 8 cycles; therefore, 10 cycles is now mostly used as a guideline and is written into treatment as a guide for clinical practice. For such patients, chemotherapy is the primary treatment modality, and therefore, multiple cycles are important to inhibit tumor progression. In conclusion, the application of chemotherapy either with a guideline of 6 cycles or 10 cycles, in fact, current studies in prostate cancer suggest that the application of more cycles may be able to further improve the prognosis of patients, therefore, more aggressive treatment is still acceptable as long as the patient is generally well tolerated, can tolerate the toxic effects of chemotherapy, and the disease is not progressing.